| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/13/2006 | CA2582403A1 Pharmaceutical compositions comprising fenofibrate and atorvastatin |
| 04/13/2006 | CA2582327A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 04/13/2006 | CA2582318A1 Globin digest containing, yeast-fermented beverages |
| 04/13/2006 | CA2581798A1 A pharmaceutical formulation comprising crystalline insulin and dissolved insulin |
| 04/13/2006 | CA2581596A1 Combinations of substituted azetidonones and cb1 antagonists |
| 04/13/2006 | CA2574500A1 D-pyranosyl-substituted phenyls, medicaments containing said compounds, use thereof, and method for the production thereof |
| 04/12/2006 | EP1645624A1 Nerve cells obtained by electrical pulse treatment es cell |
| 04/12/2006 | EP1645558A1 Piperazinylpyrazines as serotonin 5-HT2C receptor modulators |
| 04/12/2006 | EP1645557A1 Novel substance having alpha-glucosidase inhibiting activity and food containing the same |
| 04/12/2006 | EP1645287A2 Anhydrous topical skin preparations |
| 04/12/2006 | EP1645198A1 Process for producing liquid formulation containing raw yeast and liquid formulation |
| 04/12/2006 | EP1644494A2 Alcohol dehydrogenase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases |
| 04/12/2006 | EP1644490A2 Transgenic cells |
| 04/12/2006 | EP1644406A2 Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 04/12/2006 | EP1644375A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 04/12/2006 | EP1644368A1 Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators |
| 04/12/2006 | EP1644364A1 Tetrazol benzofurancarboxamides with pi3k activity as therapeutic agents |
| 04/12/2006 | EP1644360A1 3-substituted indoles and derivatives thereof as therapeutic agents |
| 04/12/2006 | EP1644357A1 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 04/12/2006 | EP1644086A1 Use of whey permeate for the treatment of metabolic syndrome |
| 04/12/2006 | EP1644029A2 Use of dg008, dg065, dg210 or dg 239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 04/12/2006 | EP1644027A1 Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 04/12/2006 | EP1644023A2 Melanocortin recptor 4(mc4) agonists and their uses |
| 04/12/2006 | EP1644022A1 Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| 04/12/2006 | EP1643999A1 Pyridoxamine for the treatment of diabetic kidney disease |
| 04/12/2006 | EP1643997A1 Flupirtine preparation for treating neurodegenerative disorders of the visual system and diabetes mellitus |
| 04/12/2006 | EP1643988A1 Substituted pyrrole derivatives as hmg-coa reductase inhibitors |
| 04/12/2006 | EP1560826B1 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same |
| 04/12/2006 | EP1554278B1 Xanthine derivatives, production thereof and use thereof as medicines |
| 04/12/2006 | EP1414433B1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| 04/12/2006 | EP1395133B1 Polymer controlled induced viscosity fiber system and uses thereof |
| 04/12/2006 | EP1395132B1 Dual viscosity fibre system and uses thereof |
| 04/12/2006 | EP1355639B1 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists |
| 04/12/2006 | EP1345920B1 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/12/2006 | EP1331940B1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 04/12/2006 | EP1233767B1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 04/12/2006 | EP1202639B1 Method for suppressing appetite |
| 04/12/2006 | EP1144435B1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 04/12/2006 | EP1054887B1 Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists |
| 04/12/2006 | EP0938328B1 Method of inhibiting fibrosis with a somatostatin agonist |
| 04/12/2006 | CN1758913A Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species |
| 04/12/2006 | CN1758906A Compositions for the improvement of obesity |
| 04/12/2006 | CN1758856A Dietary method for modulatng glucose metabolism and associated conditions and increasing longevity |
| 04/12/2006 | CN1757648A Mangiferin derivatives and its prepn. method, and use as medicine |
| 04/12/2006 | CN1757637A Method for purifying VE nicotinate raw material |
| 04/12/2006 | CN1757405A Health-care medicated wine for treating hyperlipidemia |
| 04/12/2006 | CN1757397A Biological deodorization method for dried oviduct fat of forest frog |
| 04/12/2006 | CN1757396A Ursine fat injection emulsion, and its prepn. method |
| 04/12/2006 | CN1757389A Implanted agent for preventing and treating biabetic retinopathy |
| 04/12/2006 | CN1250717C Human Enzymes of metalloprotease family |
| 04/12/2006 | CN1250563C Androgen glycosides and androgenic activity thereof |
| 04/12/2006 | CN1250553C Antidepressant azaheterocyclylmethyl derivatives of 2, 3-dihydro-1,4-dioxino [2,3-f] quinoxaline |
| 04/12/2006 | CN1250549C Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
| 04/12/2006 | CN1250526C Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 04/12/2006 | CN1250286C Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 04/12/2006 | CN1250280C Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 04/12/2006 | CN1250252C Health food of haw extractive with phenformin function |
| 04/12/2006 | CN1250246C Medicinal mixture possessing alpha glycocidase inhibiting activity and its use |
| 04/12/2006 | CN1250244C Composition for preventing and treating hyperlipidemia |
| 04/12/2006 | CN1250226C Pharmaceutical combination comprising either (S)-20ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tboc amino-phenyl)ethoxy]phenyl}-(S)-2-ethoxy propionic ac |
| 04/12/2006 | CN1250223C Pyrrolo-triazine and pyrimidine compounds |
| 04/12/2006 | CN1250212C Composition for improving lipids in blood |
| 04/12/2006 | CN1250210C The use of sulfonylureas and sulphonyl thiourea derivative in preparation of anti diabetes drug |
| 04/11/2006 | US7026516 Compounds with high monoamine transporter affinity |
| 04/11/2006 | US7026508 Succinate salt of O-desmethyl-venlafaxine |
| 04/11/2006 | US7026507 Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate |
| 04/11/2006 | US7026501 Inhibitors of α4 mediated cell adhesion |
| 04/11/2006 | US7026491 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 04/11/2006 | US7026487 Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity |
| 04/11/2006 | US7026476 Intermediate arylamine compounds |
| 04/11/2006 | US7026356 Fatty acid analogues for the treatment of diseases caused by the pathological proliferation of smooth muscle cells |
| 04/11/2006 | US7026349 Sulfonamides |
| 04/11/2006 | US7026335 Melanocortin receptor ligands |
| 04/11/2006 | US7026331 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 04/11/2006 | US7026326 Substituted heterocyclic compounds and methods of use |
| 04/11/2006 | US7026321 piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction |
| 04/11/2006 | US7026316 (optionally aza)cycloalkyl-N,N-optionally thia-, oxothia- or dioxothia-)alkyleneglycine derivatives, e.g., N-{4-[(1S)-1-amino-2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]cyclohexyl}-N'-hexylureA; especially treating type 2 diabetes |
| 04/11/2006 | US7026314 Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist |
| 04/11/2006 | US7026311 Dibenzodiazepine derivatives, their preparation and use |
| 04/11/2006 | US7026294 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes |
| 04/11/2006 | US7026289 Method and compositions for treating hyperlipidemia and other conditions |
| 04/11/2006 | US7026005 Dehydrating; steaming; drying; freezing; pulverization |
| 04/11/2006 | US7025984 Controlling appetite; using ethyl oleate |
| 04/11/2006 | CA2089440C Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicaments containing them |
| 04/11/2006 | CA2089439C 3,5-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicament containing them |
| 04/06/2006 | WO2006036031A1 Fused furan derivative and use thereof |
| 04/06/2006 | WO2006035998A1 Modified coffee, method of roasting coffee bean, coffee-like supplement and auxiliary food |
| 04/06/2006 | WO2006035967A1 Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor |
| 04/06/2006 | WO2006035900A1 Coenzyme q10-containing emulsified composition |
| 04/06/2006 | WO2006035796A1 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF |
| 04/06/2006 | WO2006035702A1 C-peptide specific binding molecule and use thereof |
| 04/06/2006 | WO2006035459A1 An improved process for the production of derivatives of thiozolidinediones and their precursors |
| 04/06/2006 | WO2006035296A1 Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat |
| 04/06/2006 | WO2006035295A1 Process for the purification of lovastatin |
| 04/06/2006 | WO2006035286A2 Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
| 04/06/2006 | WO2006035277A2 Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
| 04/06/2006 | WO2006034804A1 Indozolone derivatives as 11b-hsd1 inhibitors |
| 04/06/2006 | WO2006009437A3 Use of aspartate for regulating glucose levels in blood |
| 04/06/2006 | WO2005100331A3 Antidiabetic agents |
| 04/06/2006 | WO2005002612A8 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |